Therapy for chronic hepatitis C: Present status

Minerva Gastroenterologica e Dietologica

Volumn 46, Issue 2, 2000, Pages 81-86

  Rizzetto, M ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

Chronic therapy; Hepatitis C; Interferons therapeutic use; Ribavirin therapeutic use

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; AMANTADINE; INTERFERON; KETOPROFEN; RECOMBINANT BETA INTERFERON; RIBAVIRIN; THYMOSIN; URSODEOXYCHOLIC ACID; VIRUS RNA;

ANOREXIA; DRUG EFFICACY; DRUG MIXTURE; DRUG TOLERANCE; DYSPNEA; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; META ANALYSIS; MONOTHERAPY; NAUSEA; PHARYNGITIS; PRURITUS; REVIEW;

EID: 0033830886     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Therapy of hepatitis C
2. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials
3. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
4. Retreatment of chronic hepatitis C with interferon
5. Re-treatment with interferon Alfa of patients with chronic hepatitis C
6. Treatment of chronic hepatitis C with high-dose interferon a-2b a multicentre study
7. Comparative efficacy of high or low dose of interferon alpha 2b in chronic hepatitis C: A randomized controlled trial
8. A randomized controlled trial of daily versus three times weekly interferon alfa-2a in patients with chronic HCV and either elevated or persistently normal ALT
9. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
10. Response to higher dose of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
11. Comparison of high initial and fixed-dose regimens of interferon alpha-2a in chronic hepatitis C: A randomized controlled trial
12. The biologic activity and molecular characterization of a novel synthetic interferon alpha species, consensus interferon
13. Treatment of chronic hepatitis C with consensus interferon: A Multicenter randomized controlled trial
14. Re-treatment of chronic hepatitis C with consensus interferon
15. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon
16. Single-dose safety/tolerability and pharmokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-inerferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects
17. Therapy of Hepatitis C: Overview
18. Hepatitis C viremia in chronic liver disease: Relationship to interferon or corticosteroid treatment
19. Cholchicine worsens the efficacy of interferon-alfa in patients with chronic hepatitis interim report of a randomized pilot study
20. Combination thymosin a 1 and lymphoblastoid interferon treatment in chronic hepatitis C
21. Combination therapy with thymosin α1 and Interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
22. Biochemistry and Clinical applications of Ribavirin
23. Ribavirin treatment for chronic hepatitis C
24. Ribavirin as therapy for chronic hepatitis C: A randomized double blind, placebo controlled trial
25. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C
26. Recombinant interferon alfa-2b alone on in combination with ribavirin for retreatment of interferon relapse in chronic hepatitis C
27. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
28. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or 24 weeks vetsus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
29. Sequential versus concomitant administration of Ribavirin and Interferon alfa-n3 in patients with chronic hepatitis C not responding to Interferon alone: Results of a randomized controlled trial